Coherus BioSciences (CHRS) Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CHRS shares.
View CHRS analyst ratings or view top-rated stocks.

7 brokerages have issued 1-year price targets for Coherus BioSciences' stock. Their CHRS share price forecasts range from $8.00 to $23.00. On average, they expect the company's share price to reach $14.63 in the next year. This suggests a possible upside of 336.6% from the stock's current price.
View analysts price targets for CHRS or view top-rated stocks among Wall Street analysts.

Coherus BioSciences' stock was trading at $7.92 on January 1st, 2023. Since then, CHRS shares have decreased by 57.7% and is now trading at $3.35.
View the best growth stocks for 2023 here.

Coherus BioSciences saw a decrease in short interest in September. As of September 15th, there was short interest totaling 14,530,000 shares, a decrease of 7.2% from the August 31st total of 15,650,000 shares. Based on an average daily trading volume, of 2,990,000 shares, the short-interest ratio is currently 4.9 days.
View Coherus BioSciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our CHRS earnings forecast.

Coherus BioSciences, Inc. (NASDAQ:CHRS) announced its quarterly earnings data on Wednesday, August, 2nd. The biotechnology company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.66) by $0.17. The biotechnology company earned $58.72 million during the quarter, compared to analyst estimates of $50.83 million.

ETFs with the largest weight of Coherus BioSciences (NASDAQ:CHRS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA).First Trust Innovation Leaders ETF (ILDR).

Coherus BioSciences updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $275.00M-, compared to the consensus revenue estimate of $266.16 million.

21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CHRS stock can currently be purchased for approximately $3.35.

Coherus BioSciences (NASDAQ:CHRS) has a market capitalization of $316.47 million and generates $211.04 million in revenue each year. The biotechnology company earns $-291,750,000.00 in net income (profit) each year or ($3.32) on an earnings per share basis.

The company employs 294 workers across the globe.

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The official website for the company is www.coherus.com. The biotechnology company can be reached via phone at (650) 649-3530 or via email at darrington@coherus.com.